Developing antiviral treatments for specific RNA viruses that could cause pandemics
Official title: DEVELOPMENT OF ANTIVIRALS FOR SPECIFIC RNA VIRAL FAMILIES OF PANDEMIC POTENTIAL
Funded at Arisan Therapeutics, INC. · NIH-10933177 · Data updated 2026-11-12
This study is working on a new antiviral treatment that could help fight off certain viruses that might cause pandemics, and it aims to make this medicine available for patients when they need it most.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Arisan Therapeutics, INC. NIH-funded |
| Lab location | 1 site (Carlsbad, UNITED STATES) |
| Project start | September 22, 2023 |
| Project end | December 31, 2025 |
| Funding year | 2023 |
| Award (this year) | $3,692,037 |
| NIH project number | 75N93023C00051-0-9999-1 |
| Project ID | NIH-10933177 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for participation or benefit from this research include individuals at risk of exposure to RNA viruses with pandemic potential.
✕Less likely to help
Patients who are not at risk of exposure to these specific RNA viruses may not receive any benefit from this research.
What this research studies
This research focuses on advancing a promising antiviral treatment aimed at specific RNA viruses with the potential to cause pandemics. The project involves a series of development activities, including preclinical testing, optimization of the drug's chemistry, and ensuring that the manufacturing processes meet regulatory standards. Patients may benefit from the eventual availability of effective antiviral therapies that can be deployed during future pandemic outbreaks.
Why it matters
Potential benefit: If successful, this research could lead to the development of effective antiviral treatments that protect patients during pandemic outbreaks.
How similar studies have gone: Other research has shown success in developing antiviral treatments for viral infections, indicating that this approach has potential.
Where this research is happening
-
Arisan Therapeutics, INC.
Carlsbad, United States Active
Researchers
- Principal investigator: Henkel, Greg — Arisan Therapeutics, INC.
- Study coordinator: Henkel, Greg
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.